Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007

Similar documents
Re-audit of Radiotherapy Waiting Times 2005

Geographical Variation in Radiotherapy Services Across the UK in 2007 and the Effect of Deprivation

Waiting Times for Suspected and Diagnosed Cancer Patients

For information only. Page 1 of 16

National Breast Cancer Audit next steps. Martin Lee

T his article is based on a recent report from

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

2010 National Survey. University College London Hospitals NHS Foundation Trust

Cancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0

National Cancer Patient Experience Survey Results. University Hospitals of Leicester NHS Trust. Published July 2016

National Cancer Patient Experience Survey Results. East Kent Hospitals University NHS Foundation Trust. Published July 2016

National Cancer Patient Experience Survey Results. Milton Keynes University Hospital NHS Foundation Trust. Published July 2016

2010 National Survey. East Kent Hospitals University NHS Trust

2010 National Survey. The North West London Hospitals NHS Trust

2010 National Survey. Royal National Orthopaedic Hospital NHS Trust

2010 National Survey. The Leeds Teaching Hospitals NHS Trust

2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust

Wales Cancer Patient Experience. Survey Aneurin Bevan University Health Board. Published January 2014

National Cancer Patient Experience Programme National Survey. Royal National Orthopaedic Hospital NHS Trust. Published September 2014

Audit Report. National Audit of Paediatric Radiology Services in Hospitals

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Wales Cancer Patient Experience Survey Hywel Dda University Health Board. Published January 2014

National Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013

Supra Network Sarcoma Advisory Group (SAG) Annual Report

Unknown Primary Service for patients at Chesterfield Royal Hospital

National Standards for Sarcoma Services

National Standards for Sarcoma Services 2009

Cancer of Unknown Primary (CUP) Protocol

National Cancer Patient Experience Programme. 2012/13 National Survey. James Paget University Hospitals NHS Foundation Trust. Published August 2013

National Cancer Patient Experience Programme. 2012/13 National Survey. Milton Keynes Hospital NHS Foundation Trust. Published August 2013

Progress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

WHERE NEXT FOR CANCER SERVICES IN NORTHERN IRELAND? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Palliative care - the opportunities. Dr David Brooks Macmillan Consultant in Palliative Medicine Chesterfield Royal Hospital

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE

Survey of networks and arrangements for HIV clinical care

LCA Lung Clinical Forum. 21 st October 2014

National Cancer Patient Experience Programme National Survey. South Tees Hospitals NHS Foundation Trust. Published September 2014

Commissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013

Quality assurance in Health Services: the paradigm of radiotherapy

Cancer of Unknown Primary (CUP)

Activity Report April 2013 March 2014

Identifying and counting people living with treatable but not curable cancer

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.

Radiotherapy Equipment Needs and Workforce Implications Cancer Services Co-ordinating Group

Acute Oncology Martin Eatock Consultant Medical Oncologist NICaN Medical Director

Ruth Howkins Deputy National Coordinator National Cancer Peer Review

Quality care. Everywhere? An audit of prostate cancer services in the UK

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

National Prostate Cancer Audit. Bill Cross June 2015

Integrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014

NCIN Conference Feedback 2015

Cancer Services Position & Recovery Plan June 2015

About Cancer Research UK

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer

TRANSFORM CANCER SERVICES

Recommendations for cross-sectional imaging in cancer management, Second edition

West Midlands Sarcoma Advisory Group

Spinal cord compression: what it means and how it can be treated

Data briefing: Reflex testing for Lynch syndrome in people diagnosed with bowel cancer under the age of 50

Clinical oncology workforce: the case for expansion Faculty of Clinical Oncology

DEPARTMENT OF ONCOLOGY ELECTIVE

Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines

Single Suspected Cancer Pathway Definitions pathway start date

Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer

West Midlands Sarcoma Advisory Group

The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 11, 2015

DRAFT SARCOMA MEASURES

Outcome following surgery for colorectal cancer

Activity Report April 2013 March 2014

An Overview of Health Economics Data and Expertise in Cancer

NICE Quality Standards and COF

Improving Outcomes for People with Sarcoma

The SABR Practice Information for oncologists. State-of-the-art care has never been closer. genesiscare.co.uk

Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Bladder Cancer Guidelines

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Dr Hilary Williams. Consultant in Medical Oncology at Velindre Cancer Centre

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

Allied Healthcare Professionals Module

Palliative Care Emergencies

Guideline for the Management of Vulval Cancer

Referral and pathways for surgically managed Carpal Tunnel Syndrome patients: guidelines and current practice

STANDARDS FOR UPPER GI CANCERS 2004

Appendix 4 Urology Care Pathways

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Overview of 2010 Hong Kong Cancer Statistics

Faster Cancer Treatment Indicators: Use cases

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

National Cancer Peer Review Programme. Radiotherapy Service Evidence Guide

Census of the Radiotherapy Radiographic Workforce in the UK, 2016

Cancer of Unknown Primary Service

Richard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme

Transcription:

Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007 K. J. Drinkwater, M. V. Williams The Royal College of Radiologists, 38 Portland Place, London W1B 1JQ, UK ABSTRACT: This is the fourth Royal College of Radiologists audit on radiotherapy waiting times. These have been conducted in 1998, 2003 and 2005 with the aim of determining how long patients wait for treatment following agreement with their doctor. This and the previous audit have used an almost identical web based tool to collect data. Results are presented on 2528 patients (2669 treatments) who commenced a course of radiotherapy in the week commencing Monday 24 th September 2007. Data were obtained from 57 (10) of NHS centres and 2/3 private centres. The results show that the percentage of patients waiting more than 28 days for radical radiotherapy dropped from 53% in 2005 to 32% in 2007. This is a significant benefit for patients but further improvement is required to meet this standard for all patients as originally recommended in 1993. Introduction Delay in access to radiotherapy allows cancers to progress [1] and become unsuitable for radical treatment [2] resulting in decreased cure rates and worse patient outcomes [3-7]. Radiotherapy waiting times audits have been conducted by the Royal College of Radiologists since 1998 [8]. The previous re-audit in 2005 [9] showed an improvement compared to the earlier round in 2003 [10]. The current re-audit was undertaken to see if waiting times have continued to improve. This study adopted the same waiting times targets as in 2005. These were set in 1993 by the Joint Council for Clinical Oncology (JCCO) [11] and by the Department of Health (DH) [12]. The targets are shown in Table 1 together with indicators used to determine whether they had been met. Terms were defined in a set of help notes for participants. The definitions are reproduced in Table 2. 1

Table 1 Waiting times targets (JCCO, Nos. 1-3; DH, Nos. 4, 5) and indicators Target Indicator 1. First oncology consultation to start of urgent radiotherapy 48 hours 2. First oncology consultation to start of palliative radiotherapy (non-severe symptoms) 2 weeks 3. First oncology consultation to start of radical radiotherapy involving complex treatment planning 4 weeks 1 4. One month from diagnosis (decision to treat) to first treatment (start date) 5. Two months from urgent GP referral for suspected cancer to first treatment (start date) % of treatments where date of booking request to date urgent radiotherapy commenced 2 days % of treatments where date of booking request to date palliative radiotherapy commenced 14 days % of treatments where date of booking request to date radical radiotherapy commenced 28 days 2 % of treatments where date of decision to treat to date radiotherapy commenced 31 days 3 % of treatments where date of urgent referral by GP to date radiotherapy commenced 62 days 3 1 Where additional specialist staging procedures are necessary. 2 Radical skin cancer patients were excluded from this indicator. 3 Where first definitive treatment. 2

Table 2 Definitions of terms Term Definition Date of booking request Date radiotherapy commenced Date of decision to treat Date of urgent GP referral Urgent (waiting list status) Palliative (treatment intent) Radical (treatment intent) First definitive treatment When a clinical oncologist and a patient have agreed to a plan of treatment including a course of radiotherapy, the clinical oncologist should complete a booking request; this date is the date a booking form request is completed or an electronic request is logged. The date of the first fraction of treatment. The date of the consultation in which the patient and clinician agree the treatment plan for first treatment. It may be the same as the date of the booking request, but only if this was completed on the same day. This is the date the GP signs the referral request and trusts must respond within 24 hours. This is locally determined according to clinical judgement. Local definitions should be used. Local definitions should be used. Normally the first intervention which is intended to remove or shrink the tumour. Where there is no definitive anticancer treatment, almost all patients will be offered a palliative intervention (e.g., stenting) or palliative care (e.g., symptom control), which should be recorded for these purposes. Materials and Methods All 57 National Health Service (NHS) and three private radiotherapy centres in the United Kingdom (UK) were invited to participate. Patients commencing treatment between Monday 24 th September and Sunday 30 th September 2007 inclusive were eligible to be included. The data collection time frame was Monday 24 th September 2007 to Friday 4 th January 2008. The web-based data collection tool (see Appendix 1) was a modified version of that used in 2005 and was designed using Snap Survey Software, Version 9. Data were analysed using Microsoft Office Excel 2003. Non-responses and don t know responses were excluded from the analysis unless stated otherwise. Data collected on dose fractionation practices will be reported elsewhere. Fifty-seven out of 57 (10) NHS centres and 2/3 (67%) private centres participated in the project. Overall the response rate was 59/60 (98%). Data on 3

2715 treatments were received. Initially, 35 (1%) sets of data were excluded. In almost all cases this was because treatment had commenced outside the specified time period. After checking for duplicate records, a further 11 (0.4%) sets of data were excluded. Two thousand six hundred and sixty-nine sets of data from 2528 patients were audited. The following analysis is in terms of cancer sites irradiated, so that data on some patients appears twice. Thirteen (0.5%) of data sets were from the private sector and 2656 (99.5%) sets were from NHS centres; these will have included patients treated privately, but this item of information has not been requested in any of these audits. Results Patient diagnoses and sites treated are shown in Figures 1 and 2 respectively. With regard to the indicators, three hundred and fifty out of 2526 (14%) treatments were urgent by waiting list status. One thousand one hundred and forty-four out of 2647 (43%) were palliative and 940/2647 (36%) were radical by treatment intent. A summary of waiting list status and treatment intent is presented in Appendix 2. Four hundred and sixty-three out of 2538 (18%) treatments were first definitive treatments, but date of urgent GP referral was supplied for only 81/463 (17%) of these. Seven hundred and thirty-one out of 2550 (29%) treatments were subject to elective delay, and were excluded from the waiting times analysis. The reasons given for elective delays are shown in Table 3. Chemotherapy/hormone therapy was the most common explanation at 367/705 (52%). Table 3 Reasons for elective delays Reason n/n (%) Chemotherapy/Hormone therapy 367/705 (52) Intercurrent illness 27/705 (4) Other 110/705 (16) Patient request (holidays etc) 137/705 (19) Post-chemotherapy delay 14/705 (2) Recovering from surgery 50/705 (7) 4

Waiting Times Analysis The cumulative percentage of urgent, palliative and radical treatments commenced at daily intervals from date of booking request and, where treatment was first definitive treatment, from date of decision to treat and date of urgent referral by GP are shown in Figures 3a, 3b, 4 and 5. Median waiting times together with each of the five waiting times targets are shown in Table 4. Table 4 Median waiting times and waiting times targets Target Median (interquartile range) First oncology consultation to start of urgent radiotherapy 48 hours First oncology consultation to start of palliative radiotherapy (non-severe symptoms) 2 weeks First oncology consultation to start of radical radiotherapy involving complex treatment planning 4 weeks One month from diagnosis (decision to treat) to first treatment (start date) Two months from urgent GP referral for suspected cancer to first treatment (start date) 12 days (6-23 days) 8 days (4-14 days) 25 days (19-32 days) 15 days (8-22 days) 54 days (34-71 days) The one month (31 days) and two month (62 days) targets only apply to England [12]. However, as a national audit project, comparisons against these targets, as well as against the 48 hours, 2 week and 4 week targets, were made for the UK as a whole (Table 5) and for England, Scotland, Wales and Northern Ireland separately (Table 6). 5

Table 5 Percentage of patients exceeding waiting times targets in the UK Target Non-compliance (%) First oncology consultation to start of urgent radiotherapy 48 hours First oncology consultation to start of palliative radiotherapy (nonsevere symptoms) 2 weeks First oncology consultation to start of radical radiotherapy involving complex treatment planning 4 weeks One month from diagnosis (decision to treat) to first treatment (start date) Two months from urgent GP referral for suspected cancer to first treatment (start date) 239/278 (86%) 218/994 (22%) 159/500 (32%) 33/393 (8%) 24/75 (32%) Table 6 - Percentage of patients exceeding waiting times targets in England, Scotland, Wales and Northern Ireland Non-compliance (%) Target England Scotland Wales Northern Ireland First oncology consultation to start of urgent radiotherapy 48 hours First oncology consultation to start of palliative radiotherapy (nonsevere symptoms) 2 weeks First oncology consultation to start of radical radiotherapy involving complex treatment planning 4 weeks One month from diagnosis (decision to treat) to first treatment (start date) Two months from urgent GP referral for suspected cancer to first treatment (start date) 184/215 (86) 36/38 (95) 11/15 (73) 8/10 (80) 177/862 (21) 28/67 (42) 12/52 (23) 1/13 (8) 126/424 (30) 17/40 (43) 16/32 (50) 0/4 (0) 22/316 (7) 5/36 (14) 6/30 (20) 0/11 (0) 17/62 (27) 5/11 (45) 1/1 (100) 1/1 (100) 6

Levels of compliance with 2 weeks and 4 weeks targets were reported by centre rating in the previous audit rounds. For the current round, they are reported by centre ID number and are shown in Figures 8 and 9. Discussion This is the fourth round of audit which the RCR has conducted over a decade. In each audit a complete dataset has been obtained from all NHS radiotherapy centres in the UK. On this occasion we also have data from two of the three private providers in London. Waiting list status categories were locally defined by each centre. Appendix 2 shows that 13% were categorised as urgent yet the median time to start treatment following the consultation was 12 days (Table 7). Table 4 and Figure 3a show that 86% were later than the JCCO target of treatment within 48 hours. It is likely that this reflects an inappropriate use of the term urgent. Similar problems have been identified in an audit of systemic therapy waiting times (paper in preparation). The JCCO did not use the term emergency but of the 3% of cases so categorised 77/79 (97 %) were treated within 48 hours. This may be a more appropriate term to identify such patients in future. Figure 3a shows that classifying a patient as urgent rather than routine only brought their treatment forward by about 4 days. Figure 3b shows that patients treated palliatively did receive treatment to relieve their symptoms sooner than patients who received radical treatment, as was the intent of the JCCO guidelines. Table 7 and Figures 6 and 7 show the percentage of patients exceeding waiting times targets in each round. 7

Table 7 - Percentage of patients exceeding waiting times targets in the UK between 1998 and 2007 Non-compliance Target Round 1 (1998) Round 2 (2003) Round 3 (2005) Round 4 (2007) First oncology consultation to start of urgent radiotherapy 48 hours First oncology consultation to start of palliative radiotherapy (nonsevere symptoms) 2 weeks First oncology consultation to start of radical radiotherapy involving complex treatment planning 4 weeks One month from diagnosis (decision to treat) to first treatment (start date) Two months from urgent GP referral for suspected cancer to first treatment (start date) - - - 86% 25% 6 33% 22% 32% 72% 53% 32% - - 29% 8% - - 26% 32% The proportion of patients waiting longer than recommended has continued to fall since the previous audit, except for the two month (62 day) target set by the Department of Health. Data for this endpoint were compromised because the date of urgent GP referral was supplied for only 81/463 (17%) of patients who were receiving their first definitive treatment (FDT). The results show that in England, the number of patients exceeding the one month target was 22/316 (7%) and for the two month target it was 17/62 (27%). Much lower levels of noncompliance of 0.3 % and 2.8% respectively were reported by the DH for the quarter in which the audit took place [13]. However, the DH figures apply to all forms of cancer treatment and not just radiotherapy. In addition there is an analytical difference because we excluded patients with an elective delay, whereas the DH analysis uses a stop the clock approach. Further research would be required to determine the cause of the discrepancy but these results are not necessarily incompatible with each other. 8

Conclusion Since 2003 there has been a steady reduction in radiotherapy waiting times for patients. This demonstrates that investment in equipment, staff and training is starting to produce benefits for patients. Investment plans have been established for Scotland [14] and Wales [15]. We welcome the recommendation in the English Cancer Reform Strategy [16] for a further 200m investment in radiotherapy to improve services for patients. It will be important that this investment addresses not only the waiting times described in this paper but also quality issues which include both the avoidance of interruptions to treatment which can have an adverse effect on patients [1] and the availability of modern and sophisticated treatment which can improve tumour control and reduce side effects. References 1 Coles CE, Burgess L, Tan LT. An audit of delays before and during radical radiotherapy for cervical cancer: effect on tumour cure probability. Clin Oncol 2003;15:47-54. 2 O Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol 2000;12:141-144. 3 O Sullivan B, Mackillop W, Grice B. The influence of delay in the initiation of definitive radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 1998;42(suppl):323. 4 Fortin A, Bairati I, Albert M, et al. Effect of treatment delay on outcome of patients with early stage head and neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:929-936. 5 Waaijer A, Terhaard CH, Dehnad H, et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol 2003;66:271-276. 6 Huang J, Barbera L, Brouwers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003;21:555-63. 7 Mikeljevic J, Haward R, Johnston C et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 2004;90:1343-8 8 Royal College of Radiologists. A national audit of waiting times for radiotherapy. London: Royal College of Radiologists, 1998. 9 Summers E, Williams M. Re-audit of radiotherapy waiting times 2005. http://www.rcr.ac.uk/index.asp?pageid=147 (last accessed 11/3/08). 10 Ash D, Barrett A, Hinks A, Squire C. Re-audit of Radiotherapy Waiting Times 2003. Clinical Oncol 2004;16:387-394. 11 Joint Council for Clinical Oncology. Reducing Delays in Cancer Treatment: Some Targets. London: The Royal College of Physicians and the Royal College of Radiologists, 1993. 9

12 Department of Health. The NHS Cancer Plan: A Plan for Investment, A Plan for Reform. Department of Health, London, September 2000. 13 http://www.performance.doh.gov.uk/cancerwaits/2007/q2/index.html (last accessed 11/3/08). 14 The Scottish Government. Cancer in Scotland: Radiotherapy Activity Planning 2011-15. (January 2006, web only, last accessed 3.4.8). http://www.scotland.gov.uk/publications/2006/01/24131719/0 15 Welsh Assembly Government. Radiotherapy Equipment Needs and Workforce Implications 2006-2016 Cancer Services Co-ordinating Group Radiotherapy & Chemotherapy Advisory Group, May 2006. (last accessed 3.4.8). http://new.wales.gov.uk/about/departments/dhss/publications/health_pub_i ndex/reports/radiotherapyequipmentneeds?lang=en 16 Department of Health. Cancer Reform Strategy. Department of Health, London, 2007. Available at: http://www.dh.gov.uk/en/publicationsandstatistics/publications/publication spolicyandguidance/dh_081006. 10

Upper GI Unknown primary Skin Sarcoma 91 (3%) 28 (1%) 153 (6%) 19 (1%) Prostate 357 (13%) Other (inc. renal, germ cell etc) Lymphoma (inc. leukaemia and myeloma) 74 (3%) 124 (5%) Lung 452 (17%) Head and Neck Gynaecological 119 (4%) 120 (4%) Don't know 4 () Colorectal 170 (6%) Central Nervous System 57 (2%) Breast 830 (31%) Bladder 70 (3%) 0 100 200 300 400 500 600 700 800 900 Frequency Fig. 1 Patient diagnosis. 11

Total body irradiation Skin Prostate Pelvis (not bone) Other (excluding bone mets) Neck nodes Limb (inc. sarcoma) Head and Neck (+/- nodes) Don't know Chest wall with nodes Chest wall Chest Breast with nodes Breast only Breast boost Brain Bone Bladder Axilla Abdomen 6 () 131 (5%) 176 (7%) 105 (4%) 38 (1%) 22 (1%) 131 (5%) 2 () 33 (1%) 89 (3%) 80 (3%) 21 (1%) 181 (7%) 39 (1%) 19 (1%) 46 (2%) 298 (11%) 316 (12%) 436 (16%) 498 (19%) 0 100 200 300 400 500 600 Frequency Fig. 2 Site treated. 12

10 9 Urgent Routine 8 7 Cumulative percentage 6 5 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 Waiting time (Days) Fig. 3a Cumulative percentage of urgent and routine treatments commenced from date of booking request. 13

10 9 Palliative Radical 8 7 Cumulative percentage 6 5 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 Waiting time (Days) Fig. 3b Cumulative percentage of palliative and radical treatments commenced from date of booking request. 14

62 64 66 68 70 72 60 58 56 54 52 10 9 8 7 6 5 Cumulative percentage 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 Waiting time (Days) Fig. 4 - Cumulative percentage of first definitive treatments commenced from date of decision to treat. 15

90 9294 96 98100 102 >103 84 8688 78 8082 10 9 8 7 6 5 Cumulative percentage 0 2 4 6 810 12 1416 18 2022 24 2628 30 3234 36 3840 42 4446 48 5052 54 5658 60 6264 66 6870 72 7476 Waiting time (Days) Fig. 5 - Cumulative percentage of first definitive treatments commenced from date of urgent referral by GP. 16

9 8 1998 2003 2005 2007 7 6 Non-compliance 5 Palliative Treatment intent Radical Fig. 6 Percentage of patient treatments exceeding JCCO waiting time targets for palliative and radical radiotherapy between 1998 and 2007. Error bars represent the standard error. 17

5 45% 2005 2007 35% Non-compliance 25% 15% 5% One month from diagnosis to first treatment Two months from urgent GP referral to first treatment Waiting time targets Fig. 7 Percentage of patient treatments exceeding DH waiting time targets between 2005 and 2007. Error bars represent the standard error. 18

Palliative 1998 Palliative 2005 10 10 9 9 8 8 7 7 6 6 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 Centre Rating Centre Rating Palliative 2003 Palliative 2007 10 10 9 9 8 8 7 6 5 Percentage complied with target 7 6 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 Centre Rating 149 208 242 266 306 332 346 379 546 3050 3051 204 623 243 325 400 130 272 179 214 270 297 165 666 150 173 910 151 128 277 152 188 509 259 226 176 160 1052 132 788 133 184 1042 167 397 1073 431 371 273 278 246 336 143 319 148 1012 299 Centre ID number Fig. 8 Percentage of patients treated within 2 weeks waiting time target between 1998 and 2007. As the curve shifts to the right, more patients are treated within the target. 19

Radical 1998 Radical 2005 10 10 9 9 8 8 7 7 6 6 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Centre Rating Centre Rating Radical 2003 Radical 2007 10 10 9 9 8 8 7 6 5 Percentage complied with target 7 6 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Centre Rating 128 130 151 167 179 208 246 266 319 346 400 431 546 666 788 910 1052 3050 332 623 132 242 297 1073 150 272 204 243 270 273 336 165 152 214 306 173 299 226 160 176 133 277 1042 259 184 188 325 148 371 509 278 143 193 1012 Centre ID number Fig. 9 Percentage of patients treated within 4 weeks waiting time target between 1998 and 2007. As the curve shifts to the right, more patients are treated within the target. 20

Appendix 1 Radiotherapy Waiting Times Re-Audit (V2.7) Q1 Q2 Q3 Q4 Centre ID Number (as allocated by the RCR audit officer) Audit identification number (one for each patient - to be allocated locally) Contact email address of person entering the data Verify contact email address Q5 Q6 Have you already submitted data about this patient - other than NRAG patient category information - AND now you want to submit NRAG patient category information? Yes (You will be directed to Q23) No (You will be directed to Q6) Has this patient previously received radiotherapy for any indication? (Note that two or three phase treatments are considered a single course, as is breast boost) Yes No Don't know Diagnosis Q7 Patient Diagnosis Bladder Breast Central Nervous System Colorectal Gynaecological Head and Neck Lung Lymphoma (inc. leukaemia and myeloma) Prostate Sarcoma Skin Upper GI Unknown primary Other (inc. renal, germ cell etc) Don't know Site to be Treated Q8 Site Treated Abdomen Axilla Bladder Bone Brain Breast only Breast with nodes Breast boost Chest Chest wall Chest wall with nodes Head and Neck (+/- nodes) Neck nodes Limb (inc. sarcoma) Pelvis (not bone) Prostate Skin Total body irradiation Other (excluding bone mets) Don't know Prescription Details In previous rounds of this audit, there seemed to be some erroneous answers in this section (e.g. 5 Gy in 20 fractions instead of 20 Gy in 5 fractions). Please ensure that data are entered into the correct fields. Q9 Total dose (Gy) Q10 Number of FRACTIONS WARNING: NUMBER OF FRACTIONS (Q10) IS GREATER THAN TOTAL DOSE (Q9) - PLEASE QUERY YOUR DATA. Q11 Number of FRACTIONS per week 21

Dates Please enter dates dd/mm/yy (e.g. 31/03/08) Q12 Date of booking request Q13 Date patient able to start treatment. This date is requested for ALL patients. It should only differ from "Date of booking request" if there was an elective delay. Q14 Date radiotherapy commenced Q15 Was there an elective delay? Yes (if yes you will be directed to question 16 asking why there was a delay) No (You will be directed to question 17) Don't know (You will be directed to question 17) Q16 If yes why Chemotherapy/Hormone Therapy Recovering from surgery Patient request (holidays etc) Post-chemotherapy delay Intercurrent illness Other Don't know If other, please specify Treatment Intent and Priority Q17 Treatment intent Radical skin Radical non-skin Palliative Adjuvant pre-operative Adjuvant post-operative Don't know Q18 Waiting list status Emergency (within 24 hours) Urgent (category 1) Routine (category 2) Don't know Q19 Is this the patient's first definitive treatment for cancer? Yes (if yes you will be directed onto questions 20 and 21 for further dates). No (You will be directed to Q22) Don't know (You will be directed to Q22) Q20 Date of urgent referral by GP. Please enter dates dd/mm/yy (e.g. 31/03/08). If this date is unknown please leave blank. Q21 Date of decision to treat 22

Appendix 2 Number of entries submitted arranged by treatment intent and waiting list status Waiting list status Treatment intent Don t know Emergency Routine Urgent Missing Grand Total Adjuvant postoperative 2 0 382 11 0 395 Adjuvant preoperative 0 0 34 9 0 43 Don't know 7 0 14 1 0 22 Palliative 39 80 799 200 26 1144 Radical non-skin 28 0 750 123 39 940 Radical skin 0 2 115 6 2 125 Missing 0 0 0 0 0 0 Grand total 76 82 2094 350 67 2669 3% 3% 78% 13% 3% 10 23